logo
Plus   Neg
Share
Email

FMC: Paul Graves To Lead New Lithium Materials Company As CEO; Expects IPO In H2

FMC Corp. (FMC) announced that Paul Graves, executive vice president and CFO, has been appointed CEO for the new, publicly traded lithium materials company, which will be created by separating FMC's lithium business in the second half of 2018. Gilberto Antoniazzi, CFO for FMC Agricultural Solutions, has been appointed CFO for the new lithium materials company. Andrew Sandifer, FMC vice president and treasurer, has been appointed CFO and treasurer for FMC Corporation.

Tom Schneberger, vice president and global business director of FMC Lithium, has been named chief operating officer for the new lithium materials company. Pierre Brondeau will serve as chairman of the board of the new lithium materials company. He will continue to lead FMC Corporation as president, CEO and chairman.

"Preparations to separate our lithium business are progressing very well, with an expected IPO in the second half of 2018. It is important that we have a strong executive team in place well in advance of the IPO," said Brondeau.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
RELATED NEWS
Follow RTT